Reports
Reports
Sale
The global biobanking market was valued at USD 72.1 billion in 2023, with Latin America holding a significant market share. The market is driven by the growing demand for precision medicine and the rising focus on life science research. It is expected to grow at a CAGR of 6.89% during the forecast period of 2024-2032, with the values likely to attain USD 131.1 billion by 2032.
A biobank collects and stores biological samples along with associated health data of donors. They serve as a library for researchers and significantly reduce the time and resources needed to conduct a research study. There is a growing emphasis on life science research especially in the field of regenerative medicine and clinical studies which rely heavily on high-quality biological samples and thus are dependent on biobank facilities. This rising demand for well-maintained repositories that can store and manage these samples effectively is expected to drive the Latin America biobanking market growth. Additionally, the increased government initiatives and funding to support the establishment and expansion of biobanks are anticipated to impact the market dynamics.
The rising burden of chronic diseases is projected to impact the market dynamics. Recent data reveals that chronic diseases pose a major health challenge in Latin American countries with a substantial economic impact and mortality rates . Since biobanks act as a prerequisite in the development of new therapeutics and advanced diagnostic techniques, the market demand for these repositories is likely to augment in the forecast period. Moreover, the increasing technological advancements in biobanking practices to enhance research outcomes are anticipated to boost the Latin America biobanking market share.
One of the major market trends is the growing demand for precision medicine which stimulates the need for biobanking services to facilitate personalized approaches to disease treatment and diagnosis. For instance, the Florida-based biotechnology company Galatea Bio, Inc., is building a biobank to accelerate drug discovery and bring precision medicine to the untapped Latin American population. The company plans to have 10 million data points by 2026 and employs Illumina NovaSeq 6000 and NextSeq 2000 Systems to sequence genomes. Thus, the growth in the precision medicine sector is anticipated to elevate the market value in the coming years.
The report offers a detailed analysis of the market based on the following segments:
Market Breakup | Categories |
Product and Service | Equipment, Consumables, Service, Software |
Application | Regenerative Medicine, Life Science Research, Clinical Research |
Sample Type | Blood Tissue, Nucleic Acids, Cell Lines |
End User | Academic Institutions, Pharma and Biotech Companies |
Country | Brazil, Argentina, Mexico, Others |
The key features of the market report include funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
REPORT FEATURES | DETAILS |
Base Year | 2023 |
Historical Period | 2017-2023 |
Forecast Period | 2024-2032 |
Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
Breakup by Product and Service |
|
Breakup by Application |
|
Breakup by Sample Type |
|
Breakup by End User |
|
Breakup by Region |
|
Market Dynamics |
|
Supplier Landscape |
|
Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Latin America Biobanking Market Overview
3.1 Latin America Biobanking Market Historical Value (2017-2023)
3.2 Latin America Biobanking Market Forecast Value (2024-2032)
4 Latin America Biobanking Market Landscape*
4.1 Latin America Biobanking: Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Latin America Biobanking: Product Landscape
4.2.1 Analysis by Product and Service
4.2.2 Analysis by Application
5 Latin America Biobanking Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.2.1 Strengths
5.2.2 Weaknesses
5.2.3 Opportunities
5.2.4 Threats
5.3 Porter’s Five Forces Model
5.3.1 Bargaining Power of Suppliers
5.3.2 Bargaining Power of Buyers
5.3.3 Threat of New Entrants
5.3.4 Threat of Substitutes
5.3.5 Degree of Rivalry
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Latin America Biobanking Market Segmentation (2017-2032)
6.1 Latin America Biobanking Market (2017-2032) by Product and Service
6.1.1 Market Overview
6.1.2 Equipment
6.1.3 Consumables
6.1.4 Service
6.1.5 Software
6.2 Latin America Biobanking Market (2017-2032) by Application
6.2.1 Market Overview
6.2.2 Regenerative Medicine
6.2.3 Life Science Research
6.2.4 Clinical Research
6.3 Latin America Biobanking Market (2017-2032) by Sample Type
6.3.1 Market Overview
6.3.2 Blood Tissue
6.3.3 Nucleic Acids
6.3.4 Cell Lines
6.4 Latin America Biobanking Market (2017-2032) by End User
6.4.1 Market Overview
6.4.2 Academic Institutions
6.4.3 Pharma and Biotech Companies
6.5 Latin America Biobanking Market (2017-2032) by Country
6.5.1 Market Overview
6.5.2 Brazil
6.5.3 Argentina
6.5.4 Mexico
6.5.5 Others
7 Brazil Biobanking Market (2017-2032)
7.1 Brazil Biobanking Market (2017-2032) by Product and Service
7.1.1 Market Overview
7.1.2 Equipment
7.1.3 Consumables
7.1.4 Service
7.1.5 Software
7.2 Brazil Biobanking Market (2017-2032) by Application
7.2.1 Market Overview
7.2.2 Regenerative Medicine
7.2.3 Life Science Research
7.2.4 Clinical Research
7.3 Brazil Biobanking Market (2017-2032) by Sample Type
7.3.1 Market Overview
7.3.2 Blood Tissue
7.3.3 Nucleic Acids
7.3.4 Cell Lines
7.4 Brazil Biobanking Market (2017-2032) by End User
7.4.1 Market Overview
7.4.2 Academic Institutions
7.4.3 Pharma and Biotech Companies
8 Argentina Biobanking Market (2017-2032)
8.1 Argentina Biobanking Market (2017-2032) by Product and Service
8.1.1 Market Overview
8.1.2 Equipment
8.1.3 Consumables
8.1.4 Service
8.1.5 Software
8.2 Argentina Biobanking Market (2017-2032) by Application
8.2.1 Market Overview
8.2.2 Regenerative Medicine
8.2.3 Life Science Research
8.2.4 Clinical Research
8.3 Argentina Biobanking Market (2017-2032) by Sample Type
8.3.1 Market Overview
8.3.2 Blood Tissue
8.3.3 Nucleic Acids
8.3.4 Cell Lines
8.4 Argentina Biobanking Market (2017-2032) by End User
8.4.1 Market Overview
8.4.2 Academic Institutions
8.4.3 Pharma and Biotech Companies
9 Mexico Biobanking Market (2017-2032)
9.1 Mexico Biobanking Market (2017-2032) by Product and Service
9.1.1 Market Overview
9.1.2 Equipment
9.1.3 Consumables
9.1.4 Service
9.1.5 Software
9.2 Mexico Biobanking Market (2017-2032) by Application
9.2.1 Market Overview
9.2.2 Regenerative Medicine
9.2.3 Life Science Research
9.2.4 Clinical Research
9.3 Mexico Biobanking Market (2017-2032) by Sample Type
9.3.1 Market Overview
9.3.2 Blood Tissue
9.3.3 Nucleic Acids
9.3.4 Cell Lines
9.4 Mexico Biobanking Market (2017-2032) by End User
9.4.1 Market Overview
9.4.2 Academic Institutions
9.4.3 Pharma and Biotech Companies
10 Regulatory Framework
11 Funding and Investment Analysis
11.1 Analysis by Funding Instances
11.2 Analysis by Type of Funding
11.3 Analysis by Funding Amount
11.4 Analysis by Leading Players
11.5 Analysis by Leading Investors
11.6 Analysis by Geography
12 Partnership and Collaborations Analysis
12.1 Analysis by Partnership Instances
12.2 Analysis by Type of Partnership
12.3 Analysis by Leading Players
12.4 Analysis by Geography
13 Supplier Landscape
13.1 Market Share by Top 5 Companies
13.2 Thermo Fisher Scientific, Inc.
13.2.1 Financial Analysis
13.2.2 Product Portfolio
13.2.3 Demographic Reach and Achievements
13.2.4 Mergers and Acquisitions
13.2.5 Certifications
13.3 Beckman Coulter, Inc.
13.3.1 Financial Analysis
13.3.2 Product Portfolio
13.3.3 Demographic Reach and Achievements
13.3.4 Mergers and Acquisitions
13.3.5 Certifications
13.4 Tecan Trading AG
13.4.1 Financial Analysis
13.4.2 Product Portfolio
13.4.3 Demographic Reach and Achievements
13.4.4 Mergers and Acquisitions
13.4.5 Certifications
13.5 PHC Corporation
13.5.1 Financial Analysis
13.5.2 Product Portfolio
13.5.3 Demographic Reach and Achievements
13.5.4 Mergers and Acquisitions
13.5.5 Certifications
13.6 Teva Pharmaceutical Industries Ltd.
13.6.1 Financial Analysis
13.6.2 Product Portfolio
13.6.3 Demographic Reach and Achievements
13.6.4 Mergers and Acquisitions
13.6.5 Certifications
13.7 BioLife Solutions Inc.
13.7.1 Financial Analysis
13.7.2 Product Portfolio
13.7.3 Demographic Reach and Achievements
13.7.4 Mergers and Acquisitions
13.7.5 Certifications
13.8 Merck KGaA
13.8.1 Financial Analysis
13.8.2 Product Portfolio
13.8.3 Demographic Reach and Achievements
13.8.4 Mergers and Acquisitions
13.8.5 Certifications
13.9 Taylor- Wharton
13.9.1 Financial Analysis
13.9.2 Product Portfolio
13.9.3 Demographic Reach and Achievements
13.9.4 Mergers and Acquisitions
13.9.5 Certifications
13.10 Panasonic biomedical
13.10.1 Financial Analysis
13.10.2 Product Portfolio
13.10.3 Demographic
13.10.4 Mergers and Acquisitions
13.10.5 Certifications
13.11 Custom biogenic systems
13.11.1 Financial Analysis
13.11.2 Product Portfolio
13.11.3 Demographic Reach and Achievements
13.11.4 Mergers and Acquisitions
13.11.5 Certifications
14 Latin America Biobanking Market – Distribution Model (Additional Insight)
14.1 Overview
14.2 Potential Distributors
14.3 Key Parameters for Distribution Partner Assessment
15 Key Opinion Leaders (KOL) Insights (Additional Insight)
16 Company Competitiveness Analysis (Additional Insight)
16.1 Very Small Companies
16.2 Small Companies
16.3 Mid-Sized Companies
16.4 Large Companies
16.5 Very Large Companies
17 Payment Methods (Additional Insight)
17.1 Government Funded
17.2 Private Insurance
17.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
The Latin America biobanking market is expected to be driven by the rising demand for the global market, which is anticipated to grow at a CAGR of 6.89% during the forecast period of 2024-2032 and is likely to reach a market value of USD 131.1 billion by 2032.
The growing demand for precision medicine and the rising focus on life science research is fuelling the demand for the market.
One of the significant trends in the market is the growing demand for precision medicine which stimulates the need for biobanking services. Galatea Bio, Inc., is building a biobank to accelerate drug discovery and bring precision medicine to the underserved Latin American population, aiming to collect 10 million data points by 2026.
Based on the products and services, the market is segmented into equipment, consumables, services, and software.
By sample type, the market is divided into blood tissue, nucleic acids, and cell lines.
End users of the market are academic institutions, pharma, and biotech companies.
Major applications of biobanking include regenerative medicine, life science research, and clinical research.
The market segmentation by countries includes Brazil, Argentina, and Mexico, among others.
The key players in the market are Thermo Fisher Scientific, Inc., Beckman Coulter, Inc., Tecan Trading AG, PHC Corporation, Teva Pharmaceutical Industries Ltd., BioLife Solutions Inc., Merck KGaA, Taylor-Wharton, Panasonic Biomedical, and Custom Biogenic Systems.
Mini Report
Single User License
Five User License
Corporate License
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.